Mesotherapy with dutasteride, a 5-alpha reductase enzyme inhibitor used to treate benign prostatic hyperplasia, has been shown to be effective in improving hair density, thickness, texture, and color in women with female pattern hair loss (FPHL), an Egyptian study reports.
Mesotherapy with dutasteride, a 5-alpha reductase enzyme inhibitor used to treat benign prostatic hyperplasia, has been shown to be effective in improving hair density, thickness, texture, and color in women with female pattern hair loss (FPHL), an Egyptian study reports.
A total of 126 women with FPHL, characterized by reduced hair density in the crown, frontal, and parietal scalp areas, were randomized to 2 groups: 86 received microinjections of a preparation containing dutasteride 0.5 mg; 40 controls received injections of saline. The 2-mL injections were given every week for 8 consecutive weeks, then twice every 2 weeks, then once after 4 weeks. Digital photos of the scalp before and after treatment were taken at each session, hair strands were epilated from participants' scalps to determine hair count and texture, and structure of the strands was examined under electron microscope. Two weeks after the last treatment, patients were asked to self-rate improvement.
At week 18, photographic evidence of improvement was seen in 63% of the dutasteride group vs 18% of controls; mean number of strands epilated by hair pull was significantly decreased in the dutasteride group (P<0.05) but not in controls (P>0.05); and hair diameter in both groups was significantly improved (P<0.05). Self-assessments of hair color, softeness (or "fall"), and brightness were significantly higher in the treatment group than in controls (P<0.05). A negative correlation was seen between the degree of improvement and duration of FPHL (P<0.05).
Moftah N, Moftah N, Abd-Elaziz G, etal. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. JEADV. 2012. Epub ahead of print.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More